Cargando…
Early Potent Protection against Heterologous SIVsmE660 Challenge Following Live Attenuated SIV Vaccination in Mauritian Cynomolgus Macaques
BACKGROUND: Live attenuated simian immunodeficiency virus (SIV) vaccines represent the most effective means of vaccinating macaques against pathogenic SIV challenge. However, thus far, protection has been demonstrated to be more effective against homologous than heterologous strains. Immune correlat...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3154277/ https://www.ncbi.nlm.nih.gov/pubmed/21853072 http://dx.doi.org/10.1371/journal.pone.0023092 |
_version_ | 1782210000911859712 |
---|---|
author | Berry, Neil Ham, Claire Mee, Edward T. Rose, Nicola J. Mattiuzzo, Giada Jenkins, Adrian Page, Mark Elsley, William Robinson, Mark Smith, Deborah Ferguson, Deborah Towers, Greg Almond, Neil Stebbings, Richard |
author_facet | Berry, Neil Ham, Claire Mee, Edward T. Rose, Nicola J. Mattiuzzo, Giada Jenkins, Adrian Page, Mark Elsley, William Robinson, Mark Smith, Deborah Ferguson, Deborah Towers, Greg Almond, Neil Stebbings, Richard |
author_sort | Berry, Neil |
collection | PubMed |
description | BACKGROUND: Live attenuated simian immunodeficiency virus (SIV) vaccines represent the most effective means of vaccinating macaques against pathogenic SIV challenge. However, thus far, protection has been demonstrated to be more effective against homologous than heterologous strains. Immune correlates of vaccine-induced protection have also been difficult to identify, particularly those measurable in the peripheral circulation. METHODOLOGY/PRINCIPAL FINDINGS: Here we describe potent protection in 6 out of 8 Mauritian-derived cynomolgus macaques (MCM) against heterologous virus challenge with the pathogenic, uncloned SIVsmE660 viral stock following vaccination with live attenuated SIVmac251/C8. MCM provided a characterised host genetic background with limited Major Histocompatibility Complex (MHC) and TRIM5α allelic diversity. Early protection, observed as soon as 3 weeks post-vaccination, was comparable to that of 20 weeks vaccination. Recrudescence of vaccine virus was most pronounced in breakthrough cases where simultaneous identification of vaccine and challenge viruses by virus-specific PCR was indicative of active co-infection. Persistence of the vaccine virus in a range of lymphoid tissues was typified by a consistent level of SIV RNA positive cells in protected vaccinates. However, no association between MHC class I /II haplotype or TRIM5α polymorphism and study outcome was identified. CONCLUSION/SIGNIFICANCE: This SIV vaccine study, conducted in MHC-characterised MCM, demonstrated potent protection against the pathogenic, heterologous SIVsmE660 challenge stock after only 3 weeks vaccination. This level of protection against this viral stock by intravenous challenge has not been hitherto observed. The mechanism(s) of protection by vaccination with live attenuated SIV must account for the heterologous and early protection data described in this study, including those which relate to the innate immune system. |
format | Online Article Text |
id | pubmed-3154277 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-31542772011-08-18 Early Potent Protection against Heterologous SIVsmE660 Challenge Following Live Attenuated SIV Vaccination in Mauritian Cynomolgus Macaques Berry, Neil Ham, Claire Mee, Edward T. Rose, Nicola J. Mattiuzzo, Giada Jenkins, Adrian Page, Mark Elsley, William Robinson, Mark Smith, Deborah Ferguson, Deborah Towers, Greg Almond, Neil Stebbings, Richard PLoS One Research Article BACKGROUND: Live attenuated simian immunodeficiency virus (SIV) vaccines represent the most effective means of vaccinating macaques against pathogenic SIV challenge. However, thus far, protection has been demonstrated to be more effective against homologous than heterologous strains. Immune correlates of vaccine-induced protection have also been difficult to identify, particularly those measurable in the peripheral circulation. METHODOLOGY/PRINCIPAL FINDINGS: Here we describe potent protection in 6 out of 8 Mauritian-derived cynomolgus macaques (MCM) against heterologous virus challenge with the pathogenic, uncloned SIVsmE660 viral stock following vaccination with live attenuated SIVmac251/C8. MCM provided a characterised host genetic background with limited Major Histocompatibility Complex (MHC) and TRIM5α allelic diversity. Early protection, observed as soon as 3 weeks post-vaccination, was comparable to that of 20 weeks vaccination. Recrudescence of vaccine virus was most pronounced in breakthrough cases where simultaneous identification of vaccine and challenge viruses by virus-specific PCR was indicative of active co-infection. Persistence of the vaccine virus in a range of lymphoid tissues was typified by a consistent level of SIV RNA positive cells in protected vaccinates. However, no association between MHC class I /II haplotype or TRIM5α polymorphism and study outcome was identified. CONCLUSION/SIGNIFICANCE: This SIV vaccine study, conducted in MHC-characterised MCM, demonstrated potent protection against the pathogenic, heterologous SIVsmE660 challenge stock after only 3 weeks vaccination. This level of protection against this viral stock by intravenous challenge has not been hitherto observed. The mechanism(s) of protection by vaccination with live attenuated SIV must account for the heterologous and early protection data described in this study, including those which relate to the innate immune system. Public Library of Science 2011-08-10 /pmc/articles/PMC3154277/ /pubmed/21853072 http://dx.doi.org/10.1371/journal.pone.0023092 Text en Berry et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Berry, Neil Ham, Claire Mee, Edward T. Rose, Nicola J. Mattiuzzo, Giada Jenkins, Adrian Page, Mark Elsley, William Robinson, Mark Smith, Deborah Ferguson, Deborah Towers, Greg Almond, Neil Stebbings, Richard Early Potent Protection against Heterologous SIVsmE660 Challenge Following Live Attenuated SIV Vaccination in Mauritian Cynomolgus Macaques |
title | Early Potent Protection against Heterologous SIVsmE660 Challenge Following Live Attenuated SIV Vaccination in Mauritian Cynomolgus Macaques |
title_full | Early Potent Protection against Heterologous SIVsmE660 Challenge Following Live Attenuated SIV Vaccination in Mauritian Cynomolgus Macaques |
title_fullStr | Early Potent Protection against Heterologous SIVsmE660 Challenge Following Live Attenuated SIV Vaccination in Mauritian Cynomolgus Macaques |
title_full_unstemmed | Early Potent Protection against Heterologous SIVsmE660 Challenge Following Live Attenuated SIV Vaccination in Mauritian Cynomolgus Macaques |
title_short | Early Potent Protection against Heterologous SIVsmE660 Challenge Following Live Attenuated SIV Vaccination in Mauritian Cynomolgus Macaques |
title_sort | early potent protection against heterologous sivsme660 challenge following live attenuated siv vaccination in mauritian cynomolgus macaques |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3154277/ https://www.ncbi.nlm.nih.gov/pubmed/21853072 http://dx.doi.org/10.1371/journal.pone.0023092 |
work_keys_str_mv | AT berryneil earlypotentprotectionagainstheterologoussivsme660challengefollowingliveattenuatedsivvaccinationinmauritiancynomolgusmacaques AT hamclaire earlypotentprotectionagainstheterologoussivsme660challengefollowingliveattenuatedsivvaccinationinmauritiancynomolgusmacaques AT meeedwardt earlypotentprotectionagainstheterologoussivsme660challengefollowingliveattenuatedsivvaccinationinmauritiancynomolgusmacaques AT rosenicolaj earlypotentprotectionagainstheterologoussivsme660challengefollowingliveattenuatedsivvaccinationinmauritiancynomolgusmacaques AT mattiuzzogiada earlypotentprotectionagainstheterologoussivsme660challengefollowingliveattenuatedsivvaccinationinmauritiancynomolgusmacaques AT jenkinsadrian earlypotentprotectionagainstheterologoussivsme660challengefollowingliveattenuatedsivvaccinationinmauritiancynomolgusmacaques AT pagemark earlypotentprotectionagainstheterologoussivsme660challengefollowingliveattenuatedsivvaccinationinmauritiancynomolgusmacaques AT elsleywilliam earlypotentprotectionagainstheterologoussivsme660challengefollowingliveattenuatedsivvaccinationinmauritiancynomolgusmacaques AT robinsonmark earlypotentprotectionagainstheterologoussivsme660challengefollowingliveattenuatedsivvaccinationinmauritiancynomolgusmacaques AT smithdeborah earlypotentprotectionagainstheterologoussivsme660challengefollowingliveattenuatedsivvaccinationinmauritiancynomolgusmacaques AT fergusondeborah earlypotentprotectionagainstheterologoussivsme660challengefollowingliveattenuatedsivvaccinationinmauritiancynomolgusmacaques AT towersgreg earlypotentprotectionagainstheterologoussivsme660challengefollowingliveattenuatedsivvaccinationinmauritiancynomolgusmacaques AT almondneil earlypotentprotectionagainstheterologoussivsme660challengefollowingliveattenuatedsivvaccinationinmauritiancynomolgusmacaques AT stebbingsrichard earlypotentprotectionagainstheterologoussivsme660challengefollowingliveattenuatedsivvaccinationinmauritiancynomolgusmacaques |